← Leaderboards
Cynthia Ann Derdeyn
Emory University
$23,649,011
Attributed
$27,218,727
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,218,727 · 19
By mechanism
R01$21,167,405 · 5
U19$4,605,969 · 2
R21$921,063 · 2
P51$524,290 · 10
Top collaborators
- Sandrasegaram Gnanakaran5 shared
- Kelly Keisen Lee3 shared
- Kathy K Griendling2 shared
- Bernard Lassegue2 shared
- Steven Edward Bosinger1 shared
Most similar at Emory University
Same institution · by research overlap
- Patrick Sean Sullivan$49,786,126
- Rob B Stephenson$14,671,822
- Ighovwerha Ofotokun$45,259,838
- Hannah L Cooper$20,325,858
- Carlos Del Rio$49,445,541
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1Neutralizing AntibodyViralAntibodiesVirusB-LymphocytesHiv Envelope Protein Gp120AutologousResponseInfectionVariantMediatingVaccinesEpitopesPathway InteractionsAntigensMonoclonal AntibodiesPlasmaImmuneBaseGeneticVaccinationCellsBinding
Grant awards (52)
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization$1,590,054
R01 · FY2025 · AI · contact PI
Interplay of the HIV-1 Env cytoplasmic tail, Gag-MA, and membrane: resolving molecular detail and blocking assembly$1,505,957
R01 · FY2025 · AI · contact PI
Exploiting glycan holes and sequence diversity of naturally occurring HIV envelope towards the design of vaccine immunogen panels for induction of neutralization breadth$802,686
R01 · FY2025 · AI · contact PI
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization$795,027
R01 · FY2024 · AI · contact PI
Interplay of the HIV-1 Env cytoplasmic tail, Gag-MA, and membrane: resolving molecular detail and blocking assembly$774,186
R01 · FY2024 · AI · contact PI
Exploiting glycan holes and sequence diversity of naturally occurring HIV envelope towards the design of vaccine immunogen panels for induction of neutralization breadth$742,463
R01 · FY2024 · AI · contact PI
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization$699,750
R01 · FY2024 · AI · contact PI
Interplay of the HIV-1 Env cytoplasmic tail, Gag-MA, and membrane: resolving molecular detail and blocking assembly$827,566
R01 · FY2023 · AI · contact PI
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization$822,777
R01 · FY2023 · AI · contact PI
Novel treatment for respiratory distress due to SARS-CoV2 infection$195,625
R21 · FY2022 · AI
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.$877,087
R01 · FY2021 · AI · contact PI
Novel treatment for respiratory distress due to SARS-CoV2 infection$234,563
R21 · FY2021 · AI
Discovery of Novel Epitopes for Antibody Dependent Cell-mediated Cytotoxicity Against HIV-1 Infected Cells$223,125
R21 · FY2021 · AI · contact PI
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.$1,037,744
R01 · FY2020 · AI · contact PI
Discovery of Novel Epitopes for Antibody Dependent Cell-mediated Cytotoxicity Against HIV-1 Infected Cells$267,750
R21 · FY2020 · AI · contact PI
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.$1,126,153
R01 · FY2019 · AI · contact PI
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.$1,585,646
R01 · FY2018 · AI · contact PI
Humoral Immunity CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines$380,334
U19 · FY2018 · AI · contact PI
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.$1,231,309
R01 · FY2017 · AI · contact PI
Humoral Immunity CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines$402,401
U19 · FY2017 · AI · contact PI
Determinants of Neutralization Breadth in Early HIV-1 Infection$820,677
R01 · FY2016 · AI · contact PI
Humoral Immunity CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines$447,442
U19 · FY2016 · AI · contact PI
Determinants of Neutralization Breadth in Early HIV-1 Infection$820,677
R01 · FY2015 · AI · contact PI
Humoral Immunity CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines$455,069
U19 · FY2015 · AI · contact PI
Antibody Effector Function and Virology$448,984
U19 · FY2015 · AI · contact PI
Determinants of Neutralization Breadth in Early HIV-1 Infection$820,677
R01 · FY2014 · AI · contact PI
Antibody Effector Function and Virology$463,582
U19 · FY2014 · AI · contact PI
Humoral Immunity CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines$457,629
U19 · FY2014 · AI · contact PI
Determinants of Neutralization Breadth in Early HIV-1 Infection$802,340
R01 · FY2013 · AI · contact PI
Antibody Effector Function and Virology$541,666
U19 · FY2013 · AI · contact PI
Antibody Effector Function and Virology$475,145
U19 · FY2012 · AI · contact PI
Antibody Neutralization and Escape of Subtype C HIV-1$431,244
R01 · FY2012 · AI · contact PI
Antibody Effector Function and Virology$533,717
U19 · FY2011 · AI · contact PI
Antibody Neutralization and Escape of Subtype C HIV-1$431,244
R01 · FY2011 · AI · contact PI
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1$74,294
P51 · FY2011 · RR · contact PI
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES$37,201
P51 · FY2011 · RR · contact PI
Antibody Neutralization and Escape of Subtype C HIV-1$435,600
R01 · FY2010 · AI · contact PI
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1$54,827
P51 · FY2010 · RR · contact PI
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES$27,414
P51 · FY2010 · RR · contact PI
Antibody Neutralization and Escape of Subtype C HIV-1$440,000
R01 · FY2009 · AI · contact PI
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1$56,690
P51 · FY2009 · RR · contact PI
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES$28,350
P51 · FY2009 · RR · contact PI
Antibody Neutralization and Escape of Subtype C HIV-1$440,000
R01 · FY2008 · AI · contact PI
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS$67,958
P51 · FY2008 · RR · contact PI
Role of V1V2 in HIV transmission and pathogenesis$320,485
R01 · FY2007 · AI · contact PI
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS$65,453
P51 · FY2007 · RR · contact PI
Role of V1V2 in HIV transmission and pathogenesis$330,057
R01 · FY2006 · AI · contact PI
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS$59,665
P51 · FY2006 · RR · contact PI
Role of V1V2 in HIV transmission and pathogenesis$338,000
R01 · FY2005 · AI
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS$52,438
P51 · FY2005 · RR
Role of V1V2 in HIV transmission and pathogenesis$197,166
R01 · FY2004 · AI
Role of V1V2 in HIV transmission and pathogenesis$120,833
R01 · FY2004 · AI